SAN FRANCISCO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors who suffered substantial losses to submit your losses now.
Class Period: Nov. 11, 2022 – Nov. 8, 2023
Lead Plaintiff Deadline: Apr. 9, 2024
Visit: www.hbsslaw.com/investor-fraud/amlx
Contact An Attorney Now:
AMLX@hbsslaw.com
844-916-0895
Amylyx Pharmaceuticals, Inc. (AMLX) Securities Fraud Class Action:
The litigation focuses on Amylyx's repeated emphasis on commercial prospects and prescription rates for its product intended to treat patients with Lou Gehrig's disease -- RELYVRIO.
The complaint alleges that Amylyx made false and misleading statements and failed to disclose that: (1) it overstated RELYVRIO's commercial prospects; (2) patients were discontinuing treatment with RELYVRIO after 6 months; (3) the rate at which new patients were beginning treatment with RELYVRIO was declining; (4) accordingly, Amylyx overstated RELYVRIO's prescription rate; and (5) the company attempted ...